- Home
- NWG vs ALNY Comparison
NWG vs ALNY Comparison
Compare NWG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWG
- ALNY
- Stock Information
- Founded
- NWG 1727
- ALNY 2002
- Country
- NWG United Kingdom
- ALNY United States
- Employees
- NWG N/A
- ALNY N/A
- Industry
- NWG Commercial Banks
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- NWG Finance
- ALNY Health Care
- Exchange
- NWG Nasdaq
- ALNY Nasdaq
- Market Cap
- NWG 39.0B
- ALNY 34.7B
- IPO Year
- NWG N/A
- ALNY 2004
- Fundamental
- Price
- NWG $10.22
- ALNY $246.80
- Analyst Decision
- NWG Strong Buy
- ALNY Buy
- Analyst Count
- NWG 1
- ALNY 23
- Target Price
- NWG N/A
- ALNY $298.59
- AVG Volume (30 Days)
- NWG 2.5M
- ALNY 955.4K
- Earning Date
- NWG 10-25-2024
- ALNY 10-31-2024
- Dividend Yield
- NWG 5.70%
- ALNY N/A
- EPS Growth
- NWG 10.87
- ALNY N/A
- EPS
- NWG 0.70
- ALNY N/A
- Revenue
- NWG $18,754,858,592.00
- ALNY $2,094,795,000.00
- Revenue This Year
- NWG N/A
- ALNY $25.14
- Revenue Next Year
- NWG $4.61
- ALNY $17.13
- P/E Ratio
- NWG $6.72
- ALNY N/A
- Revenue Growth
- NWG N/A
- ALNY 21.54
- 52 Week Low
- NWG $5.16
- ALNY $141.98
- 52 Week High
- NWG $10.32
- ALNY $304.39
- Technical
- Relative Strength Index (RSI)
- NWG 62.60
- ALNY 38.74
- Support Level
- NWG $9.91
- ALNY $229.86
- Resistance Level
- NWG $10.17
- ALNY $271.08
- Average True Range (ATR)
- NWG 0.14
- ALNY 9.06
- MACD
- NWG -0.00
- ALNY -3.22
- Stochastic Oscillator
- NWG 75.58
- ALNY 29.87
About NWG NatWest Group plc (each representing two (2))
NatWest Group derives around 90% of its total income from the United Kingdom. The bank operates a retail, commercial, and private bank in the U.K., offering clients lending and payment services as well as asset management services.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.